乌帕替尼与度普利尤单抗在中重度特应性皮炎成人中的疗效与安全性:随机临床试验
Heads Up 是一项24周、头对头、3b期、多中心、随机、双盲、双模拟、活性对照试验,纳入692例适合系统治疗的中重度特应性皮炎成人,比较口服乌帕替尼30mg每日一次与皮下度普利尤单抗300mg每两周一次。乌帕替尼组严重感染、疱疹性湿疹、带状疱疹及实验室相关不良事件发生率更高,度普利尤单抗组结膜炎和注射部位反应发生率更高。
要点
- 乌帕替尼在第1周瘙痒NRS改善和第2周EASI75即显示优效。
- 乌帕替尼组严重感染、疱疹性湿疹、带状疱疹及实验室相关不良事件更多。
核心结论
- 治疗16周时,乌帕替尼在中重度特应性皮炎成人中疗效优于度普利尤单抗,未发现新的安全性信号。
研究设计与样本
- Heads Up为24周、头对头、3b期、多中心、随机、双盲、双模拟、活性对照临床试验。
- 纳入692例适合系统治疗的中重度特应性皮炎成人,随机1:1接受乌帕替尼30mg每日一次口服或度普利尤单抗300mg每两周一次皮下注射。
- 研究于2019年2月21日至2020年12月9日在22个国家129个中心开展,疗效分析基于意向治疗人群。
主要发现
- 乌帕替尼组严重感染、疱疹性湿疹、带状疱疹及实验室相关不良事件发生率更高,度普利尤单抗组结膜炎和注射部位反应发生率更高。
关键数值与推荐
- 主要终点为第16周达到EASI75。
- 次要终点包括第16周EASI90、EASI100、最严重瘙痒NRS较基线变化百分比、第4周瘙痒NRS变化、第2周EASI75、第1周瘙痒NRS变化及第16周瘙痒NRS改善≥4分。
- 第24周终点包括EASI75、EASI90、EASI100及最严重瘙痒NRS较基线改善≥4分。
临床怎么用
- 对于中重度特应性皮炎成人,乌帕替尼30mg每日一次在16周内显示比度普利尤单抗更优的皮损清除和瘙痒改善。
- 选择乌帕替尼时应关注严重感染、疱疹性湿疹、带状疱疹及实验室相关不良事件风险。
- 选择度普利尤单抗时应关注结膜炎和注射部位反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease with an unmet need for treatments that provide rapid and high levels of skin clearance and itch improvement. OBJECTIVE: To assess the safety and efficacy of upadacitinib vs dupilumab in adults with moderate-to-severe AD. DESIGN, SETTING, AND PARTICIPANTS: Heads Up was a 24-week, head-to-head, phase 3b, multicenter, randomized, double-blinded, double-dummy, active-controlled clinical trial comparing the safety and efficacy of upadacitinib with dupilumab among 692 adults with moderate-to-severe AD who were candidates for systemic therapy. The study was conducted from February 21, 2019, to December 9, 2020, at 129 centers located in 22 countries across Europe, North and South America, Oceania, and the Asia-Pacific region. Efficacy analyses were conducted in the intent-to-treat population. INTERVENTIONS: Patients were randomized 1:1 and treated with oral upadacitinib, 30 mg once daily, or subcutaneous dupilumab, 300 mg every other week. MAIN OUTCOMES AND MEASURES: The primary end point was achievement of 75% improvement in the Eczema Area and Severity Index (EASI75) at week 16. Secondary end points were percentage change from baseline in the Worst Pruritus Numerical Rating Scale (NRS) (weekly average), proportion of patients achieving EASI100 and EASI90 at week 16, percentage change from baseline in Worst Pruritus NRS at week 4, proportion of patients achieving EASI75 at week 2, percentage change from baseline in Worst Pruritus NRS (weekly average) at week 1, and Worst Pruritus NRS (weekly average) improvement of 4 points or more at week 16. End points at week 24 included EASI75, EASI90, EASI100, and improvement of 4 points or more in Worst Pruritus NRS from baseline (weekly average). Safety was assessed as treatment-emergent adverse events in all patients receiving 1 or more dose of either drug. RESULTS: Of 924 patients screened, 348 (183 men [52.6%]; mean [SD] age, 36.6 [14.6] years) were randomized to receive upadacitinib and 344 were randomized to receive dupilumab (194 men [56.4%]; mean [SD] age, 36.9 [14.1] years); demographic and disease characteristics were balanced among treatment groups. At week 16, 247 patients receiving upadacitinib (71.0%) and 210 patients receiving dupilumab (61.1%) achieved EASI75 (P = .006). All ranked secondary end points also demonstrated the superiority of upadacitinib vs dupilumab, including improvement in Worst Pruritus NRS as early as week 1 (mean [SE], 31.4% [1.7%] vs 8.8% [1.8%]; P < .001), achievement of EASI75 as early as week 2 (152 [43.7%] vs 60 [17.4%]; P < .001), and achievement of EASI100 at week 16 (97 [27.9%] vs 26 [7.6%]; P < .001). Rates of serious infection, eczema herpeticum, herpes zoster, and laboratory-related adverse events were higher for patients who received upadacitinib, whereas rates of conjunctivitis and injection-site reactions were higher for patients who received dupilumab. CONCLUSIONS AND RELEVANCE: During 16 weeks of treatment, upadacitinib demonstrated superior efficacy vs dupilumab in patients with moderate-to-severe AD, with no new safety signals. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03738397.
引用
- Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2021. PMID: 34347860. doi:10.1001/jamadermatol.2021.3023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。